格隆汇12月29日｜12月30日(周二)，将有6只新股在港交所主板上市，港交所大厅将再现六锣齐鸣(上一 次有六面铜锣同时敲响是在7月9日)。6家公司分别是： 卧安机器人(6600.HK)：暗盘收跌8.67%报67.4港元。 人工智能(AI)驱动药物发现及开发公司英矽智能(3696.HK)：暗盘收涨53.26%报36.86港元； 预制钢结构建筑服务提供商美联股份(2671.HK)：暗盘收涨18.31%报8.4港元； 中国数据基础设施及分析公司迅策(3317.HK)：暗盘收涨2.04%报48.98港元； 中国数字孪生科技公司五一视界(6651.HK)：暗盘收涨23.54%报37.68港元； 中国高端国货护肤品牌林清轩(2657.HK)：暗盘收涨18.75%报92.35港元； ...

Core Viewpoint - The company emphasizes the importance of technological innovation and sustainable development in its operations [1] Group 1: Technological Innovation - The company plans to utilize AI technology to enhance innovation in drug development across various stages [1] Group 2: Sustainable Practices - The company's rice endosperm cell bioreactor is characterized as a plant-based manufacturing process, highlighting its environmentally friendly attributes [1]

经济观察网2025年12月16日，北京哲源科技有限责任公司宣布完成亿元A1轮融资。本轮融资由国科投 资领投，泽源基金、睿智医药（300149）跟投。 哲源科技本轮资金将主要用于核心药物管线的持续推进，高价值创新IP的全球专利布局，以及计算医学 平台的升级，助力公司持续释放"药物IP创新工厂"的能力，推动生物医药产业的研发范式变革。 在复杂疾病的药物研发领域，哲源科技正在加速推进多管线布局。当前面向胰腺癌、中枢神经系统肿 瘤、脊索瘤、肝癌等疾病领域的多个自主研发药物管线，均在推进中 ...

全球健康药物研发中心成立于2016年，是由北京市政府、清华大学和盖茨基金会三方共同发起、独立运 营的非营利研究机构。此次发布的"AI孔明"药物研发平台从2017年开发至今，已实现从"靶点结构分析 →AI分子生成与优化→活性筛选→成药性评估"的药物设计全流程无缝覆盖，打通了早期药物发现的关 键技术链条。"AI孔明具备普惠性，希望它能真正打破传统药物研发中的流程壁垒和技术的垄断，打造 一个提升药物研发效率，提高成功率的关键节点。"GHDDI首席运营官陆漫春博士说。 传统的药物开发模式被形容为10年10亿美元，成功率极低。GHDDI数据科学部负责人郭晋疆博士解 释，药物研发过程类似走迷宫和大海捞针，需要不断试错才能找到满足安全、有效等要求的候选分子， 这个过程循环往复导致开发周期和成本极高。也因此，近些年来业内正在探索使用AI技术帮助研发人 员定位最优研发路径、提高研发效率。随着以大模型为代表的新一代人工智能技术走红，这一技术路径 也被纳入医药行业探索范围。 郭晋疆解释，此前使用AI参与药物研发，研究人员仍需要在已知化合物库内"大海捞针"，通过搜索筛选 出可能的活性分子再开展后续试验，效率仍然偏低且存在专利保护矛盾 ...

智通财经APP讯，碧生源(00926)发布公告，公司预期将就其对ERX Pharmaceuticals Inc.(一家根据特拉华 州法律注册成立的临床阶段生物医药公司)的投资录得重大公允值亏损约人民币1630万元。该公允值亏 损的产生主要是由于美国资本市场环境近期出现转变，投资者资金明显倾向人工智能(AI)等科技板块， 导致传统药物开发及临床研究的融资活动低迷，令ERX新药开发活动缺乏外部资金。此融资困难对ERX 的短期估值造成压力，导致ERX的估值大幅下降。 ERX最近建议增资600万美元以巩固其财务状况及为持续经营业务提供资金。为防止摊薄进一步侵蚀其 投资价值，于2025年12月12日，董事会决议参与是次增资，以维持其于ERX现有约3%持股量。 董事会认为公允值亏损将不会对公司现有业务、运营或财务状况造成任何重大不利影响。集团的流动资 金维持强劲，其整体财务及运营状况亦维持稳健。 董事会认为，进一步投资将符合公司及股东的整体利益，理由如下： ERX专注于治疗肥胖及肥胖相关代谢性疾病的创新药物的发现及临床开发，与公司的核心业务分部产生 协同效应。于投资及本公告日期，ERX及其最终实益拥有人各自独立于公司及其 ...

Core Viewpoint - The AI-driven drug development platform, DeepMind, has successfully completed a nearly $50 million Series D financing round, indicating strong investor confidence in the company's potential and growth prospects [1][1]. Financing Details - The Series D financing round was led by Dinghui Baifu, with participation from existing investors including New Ding Capital and Sequoia China [1][1]. - The financial advisory for this round was provided exclusively by Index Capital [1][1].

本轮资金将主要用于加速其全原子模型蛋白质设计平台Pallatom的技术迭代、商业化产品管线的拓展以 及全球化人才的引进。需要特别指出的是，Pallatom在全球首次解决了混旋性环肽设计难题，为新一代 环肽药物的管线开发开辟了新路径。 12月9日，AI蛋白质设计领域的领先企业杭州力文所生物科技有限公司（Levinthal Biotech，以下简 称"力文所"）宣布成功完成数千万人民币Pre-A轮融资。本轮融资由金雨茂物领投，君科丹木跟投，舟 渡资本担任独家财务顾问。 ...

专题：复旦大学"对话"系列讲座：AI与大学之未来 复旦大学"对话"系列讲座"AI与大学之未来"于12月8日举行。生命科学家、维亚生物计算化学及AI平台 执行总监钱玥在演讲中表示，AI 作为高效辅助工具，正加速药物研发流程、降低研发成本，而非取代 科研人员，为生物医药行业发展注入全新动能。 钱玥介绍，AI 在药物设计领域的应用并非一蹴而就。上世纪机器学习概念提出后，基础模型率先落 地；进入 21 世纪，深度学习网络实现突破，能够提炼生物数据、化学结构等核心特征并进行预测；而 最新一代大语言模型则完成了从预测到生成与设计的关键跨越，通过蛋白语言模型、分子语言模型等领 域化适配，充分挖掘海量数据价值，赋能药物设计全流程。 "AI 驱动的药物设计核心在于'干湿实验一体化'与多学科深度绑定。" 钱玥表示，这一模式整合了结构 生物学、药物化学、药效毒理等传统学科，结合 AI 工具的特征提取、预测、生成等功能，形成 "数据 驱动" 与 "原理驱动" 双轮并行的 AI 引擎。湿实验环节涵盖蛋白结构解析、高通量筛选、药物合成与药 效研究等步骤，为 AI 模型提供核心生物学数据；AI 引擎则基于物理原理与海量数据进行分析迭代，二 ...

Core Insights - The recent innovation summit held by Lubrizol in Pudong showcased several cutting-edge technologies, marking the Asia-Pacific debut of multiple products, while Honeywell also presented its advancements in avionics technology tailored to the needs of China's civil aviation industry [1][5] Group 1: Local Innovation and Development - Lubrizol is transitioning from "import and digest" to "source innovation" in the Asia-Pacific region, significantly increasing the proportion of local R&D through close collaboration with ecosystem partners [2][4] - The "Lubrizol CV1150 heavy-duty diesel engine oil solution" is a notable local innovation, fully developed by Lubrizol's Chinese R&D team, meeting China's National VI and pre-research National VII standards [4] - The establishment of Lubrizol's beauty research lab in Pudong has enhanced local R&D efficiency and enriched the global innovation perspective, demonstrating the company's commitment to localizing its development processes [6][7] Group 2: Technological Advancements in Aviation - Honeywell's new ground warning software, SURF-A, enhances runway safety by helping pilots identify potential hazards, showcasing the integrated advantages of Honeywell's avionics systems [5] - Honeywell is deepening its local presence in China by building a comprehensive maintenance, repair, and overhaul (MRO) network, contributing to the high-quality development of the Chinese aviation industry [5] Group 3: Regional Ecosystem and Collaboration - Pudong is recognized as a key location for multinational companies to establish their supply chains and innovation networks, attracting numerous R&D centers and innovation platforms [1][7] - Companies like bioMérieux and Eli Lilly are expanding their local operations in Pudong, focusing on collaborative innovation and transforming from import-export trade to local R&D and manufacturing [8][9]

Core Viewpoint - The article discusses a novel non-absorptive carrier-drug conjugate (CaDC) strategy targeting TGR5, which shows promise in improving glycemic control while minimizing liver toxicity associated with traditional TGR5 agonists [2][3][4]. Group 1: Research Findings - TGR5 is an important GPCR expressed in the gastrointestinal tract that, when activated, promotes GLP-1 secretion and plays a role in glucose utilization [2]. - The newly developed TGR5-targeted CaDC demonstrates superior glycemic control compared to the GLP-1 receptor agonist liraglutide, addressing the challenge of liver toxicity in TGR5 agonist development [3][7]. - The CaDC is designed to remain localized in the intestinal lumen, ensuring sustained activation of TGR5 without entering systemic circulation, thus enhancing safety [4][6]. Group 2: Mechanism and Efficacy - The TGR5-CaDC utilizes a biomimetic receptor agonist with a mesoporous silica particle framework, modified with deoxycholic acid as the TGR5 agonist, allowing for prolonged retention in the gut [4][6]. - In studies with diabetic mice and miniature pigs, TGR5-CaDC exhibited sustained blood sugar-lowering effects and lower toxicity compared to deoxycholic acid or liraglutide alone [7]. Group 3: Broader Implications - The design concept of CaDC, which targets the extracellular binding domain and mimics natural ligand-receptor interactions, has potential applications in various gastrointestinal diseases mediated by GPCRs [9].